🔹 Adj EPS: $6.74 (Est. $6.35) 🟢; +4% YoY
🔹 Revenue: $65.45 B (Est. $60.46 B) 🟢; +14% YoY
🔹 MCR: 82.2 % (Est. 82.4%) 🟢; +230 bps YoY
🔹 Adjusted Income from Operations: $1.84 B; –2% YoY
🔹 SG&A Expense Ratio: 5.8% (vs 6.4%)
FY25 Guidance:
🔹 Adj. EPS: ≥ $29.60 (Prior ≥ $29.50; Est. $29.60) 🟡
🔹 Evernorth Adj. Op. Income (pre-tax): ≥ $7.20 B
🔹 Cigna Healthcare Adj. Op. Income (pre-tax): ≥ $4.125 B
🔹 Cigna Healthcare MCR Outlook: 83.2 % – 84.2 %
Segment Performance
Evernorth Health Services
🔹 Adjusted Revenue: $53.68 B; +16 % YoY
• Pharmacy Benefit Services: $29.74 B; +14 % YoY
• Specialty & Care Services: $23.94 B; +19 % YoY
🔹 Pre-tax Adj. Op. Income: $1.43 B; +5 % YoY
🔹 Pre-tax Margin: 2.7 % (–20 bps YoY)
Cigna Healthcare
🔹 Adjusted Revenue: $14.48 B; +9 % YoY
🔹 Pre-tax Adj. Op. Income: $1.29 B; –4 % YoY
🔹 Medical Care Ratio: 82.2 % (+230 bps YoY)
Customer Metrics
🔹 Total Pharmacy Customers: 122.3 M; +3 % QoQ
🔹 Total Medical Customers: 18.0 M; –6 % QoQ (ex-Medicare divestiture, flat)
Commentary & Strategic Updates
🔸 CEO David Cordani: “Our diversified growth engines—Evernorth and Cigna Healthcare—drove a strong start to 2025; increased transparency and affordability remain core.”
🔸 Completed $3.7 B Medicare-business divestiture to HCSC on Mar 19 2025.
🔸 Repurchased 8.2 M shares YTD for $2.6 B; reiterates commitment to balanced capital deployment.